Literature DB >> 2414323

Selective expression of phosphoribosylpyrophosphate synthetase superactivity in human lymphoblast lines.

M J Losman, D Rimon, M Kim, M A Becker.   

Abstract

Phenotypic expression of 5-phosphoribosyl 1-pyrophosphate (PRPP) synthetase superactivity was examined in lymphoblast lines derived from six unrelated male patients. Fibroblasts from these individuals have increased rates of PRPP and purine nucleotide synthesis and express four classes of kinetic derangement underlying enzyme superactivity: increased maximal reaction velocity (catalytic defect); inhibitor resistance (regulatory defect); increased substrate affinity (substrate binding defect); and combined catalytic and regulatory defects. Lymphoblast lines from three patients with catalytic defects and from three normal individuals were indistinguishable with respect to enzyme activities, PRPP concentrations and generation, and rates of purine synthesis. Enzyme in lymphoblasts from a patient with combined defects also showed normal maximal reaction velocity but expressed purine nucleotide inhibitor resistance. A second regulatory defect and a substrate binding defect were also demonstrable in lymphoblasts and were identical to the enzyme defects in fibroblasts from the respective patients. Regulatory and substrate binding defects in lymphoblasts were accompanied by increased rates of PRPP and purine nucleotide synthesis. Among explanations for selective expression of enzyme superactivity, reduced concentrations of catalytically superactive enzymes seemed unlikely: immunoreactive PRPP synthetase was comparable in normal-derived and patient-derived cells. Activation of normal enzyme in transformed lymphocytes was also unlikely because absolute specific activities of lymphoblast PRPP synthetases corresponded to those of normal fibroblast and erythrocyte enzymes. Abnormal electrophoretic mobilities and thermal stabilities, identified in certain catalytically superactive fibroblast PRPP synthetases, were not found in the corresponding lymphoblast enzymes. Thus, lymphoblast PRPP synthetases from patients with catalytic superactivity appeared to differ structurally and functionally from their fibroblast counterparts.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414323      PMCID: PMC424156          DOI: 10.1172/JCI112151

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  X-linked pattern of inheritance of gout due to mutant feedback-resistant phosphoribosylpyrophosphate synthetase.

Authors:  E Zoref; A de Vries; O Sperling
Journal:  Adv Exp Med Biol       Date:  1977       Impact factor: 2.622

2.  Effects of nicotinic acid on human fibroblast purine biosynthesis.

Authors:  J A Boyle; K O Raivio; M A Becker; J E Seegmiller
Journal:  Biochim Biophys Acta       Date:  1972-05-10

3.  Human phosphoribosylpyrophosphate synthetase. Kinetic mechanism and end product inhibition.

Authors:  I H Fox; W N Kelley
Journal:  J Biol Chem       Date:  1972-04-10       Impact factor: 5.157

4.  Regulation of the synthesis of 5-phosphoribosyl-I-pyrophosphate in intact red blood cells and in cell-free preparations.

Authors:  A Hershko; A Razin; J Mager
Journal:  Biochim Biophys Acta       Date:  1969-06-17

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

7.  Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase.

Authors:  F M Rosenbloom; J F Henderson; I C Caldwell; W N Kelley; J E Seegmiller
Journal:  J Biol Chem       Date:  1968-03-25       Impact factor: 5.157

8.  A new disorder of purine metabolism with behavioral manifestations.

Authors:  W L Nyhan; J A James; A J Teberg; L Sweetman; L G Nelson
Journal:  J Pediatr       Date:  1969-01       Impact factor: 4.406

9.  Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro.

Authors:  G W Crabtree; J F Henderson
Journal:  Cancer Res       Date:  1971-07       Impact factor: 12.701

10.  Biochemically marked lymphocytoid lines: establishment of Lesch-Nyhan cells.

Authors:  K W Choi; A D Bloom
Journal:  Science       Date:  1970-10-02       Impact factor: 47.728

View more
  1 in total

1.  The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity.

Authors:  M A Becker; P R Smith; W Taylor; R Mustafi; R L Switzer
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.